Pulmatrix Q2 2023: cash $25.8M, net loss $3.8M; PUR1900 Phase 2b enrollment ongoing, topline Q3 2024

Pulmatrix, Inc.

2023-Q2 EPS reported -$2.26 vs consensus -$1.06 ▼ miss (-113.0%)

Cash and cash equivalents $25.8M as of June 30, 2023; projected runway into Q1 2025.
Q2 revenue $1.8M (up from $1.3M YoY); net loss $3.8M ($1.04 per share).
PUR1900 Phase 2b for ABPA enrolling; 13 sites active; topline data expected Q3 2024.
IND filed for PUR3100 Phase 2 in acute migraine; partnership needed to start trial.
Phase 1b data for PUR1800 in AECOPD presented; partnership opportunities being pursued.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Pulmatrix, Inc. reported financial results for the second fiscal quarter ended June 30, 2023.

Period: the second fiscal quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 10, 2023, Pulmatrix, Inc. issued a press release announcing its financial results for the second fiscal quarter ended June 30, 2023 and provided a corporate update.

View on SEC.gov

Browse all earnings releases →

Pulmatrix, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-027464

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.